Literature DB >> 9130041

Human cytomegalovirus cell tropism and pathogenesis.

C Sinzger1, G Jahn.   

Abstract

The human cytomegalovirus (HCMV) can cause lifelong infection with episodes of endogenous reactivation. Intrauterine fetal infection and infection of immunocompromised patients are well known to result in significant morbidity. Studies on HCMV cell tropism in vivo revealed three characteristics: (1) ubiquitously distributed cell types such as epithelial cells, endothelial cells and fibroblasts are the major targets of HCMV infection; (2) leukocytes circulating in the peripheral blood are susceptible to the virus, and (3) specialized parenchymal cells such as smooth muscle cells in the gastrointestinal tract and hepatocytes can also be infected. Questions to be resolved are, how the virus spreads throughout the organism, how it can impair the function of infected organs, and how it evades the host's immune response to establish lifelong infection. This chapter is focused on the role of HCMV-infected target cells for the pathogenesis of HCMV-associated disease in the acutely infected immunocompromised host.

Entities:  

Mesh:

Year:  1996        PMID: 9130041     DOI: 10.1159/000150502

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  80 in total

1.  Cytomegalovirus induces cytokine and chemokine production differentially in microglia and astrocytes: antiviral implications.

Authors:  M C Cheeran; S Hu; S L Yager; G Gekker; P K Peterson; J R Lokensgard
Journal:  J Neurovirol       Date:  2001-04       Impact factor: 2.643

2.  The human cytomegalovirus major immediate-early enhancer determines the efficiency of immediate-early gene transcription and viral replication in permissive cells at low multiplicity of infection.

Authors:  Hiroki Isomura; Mark F Stinski
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 3.  Human cytomegalovirus infection and atherothrombosis.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

4.  Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus.

Authors:  Laura Hertel; Vashti G Lacaille; Herbert Strobl; Elizabeth D Mellins; Edward S Mocarski
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

5.  The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates.

Authors:  Lucy Rasmussen; Aimee Geissler; Catherine Cowan; Amanda Chase; Mark Winters
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Viral binding-induced signaling drives a unique and extended intracellular trafficking pattern during infection of primary monocytes.

Authors:  Jung Heon Kim; Donna Collins-McMillen; Patrizia Caposio; Andrew D Yurochko
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

7.  Human cytomegalovirus infects Caco-2 intestinal epithelial cells basolaterally regardless of the differentiation state.

Authors:  A Esclatine; M Lemullois; A L Servin; A M Quero; M Geniteau-Legendre
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility.

Authors:  Gary Chan; Maciej T Nogalski; Andrew D Yurochko
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

9.  Transcriptome analysis reveals human cytomegalovirus reprograms monocyte differentiation toward an M1 macrophage.

Authors:  Gary Chan; Elizabeth R Bivins-Smith; M Shane Smith; Patrick M Smith; Andrew D Yurochko
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence.

Authors:  M Shane Smith; Gretchen L Bentz; J Steven Alexander; Andrew D Yurochko
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.